Exploring Cutting-Edge Approaches to Potentiate Mesenchymal Stem Cell and Exosome Therapy for Myocardial Infarction.
Chendong PengJie YanYu'ang JiangLin WuMiaoling LiXinrong FanPublished in: Journal of cardiovascular translational research (2023)
Cardiovascular diseases (CVDs) continue to be a significant global health concern. Many studies have reported promising outcomes from using MSCs and their secreted exosomes in managing various cardiovascular-related diseases like myocardial infarction (MI). MSCs and exosomes have demonstrated considerable potential in promoting regeneration and neovascularization, as well as exerting beneficial effects against apoptosis, remodeling, and inflammation in cases of myocardial infarction. Nonetheless, ensuring the durability and effectiveness of MSCs and exosomes following in vivo transplantation remains a significant concern. Recently, novel methods have emerged to improve their effectiveness and robustness, such as employing preconditioning statuses, modifying MSC and their exosomes, targeted drug delivery with exosomes, biomaterials, and combination therapy. Herein, we summarize the novel approaches that intensify the therapeutic application of MSC and their derived exosomes in treating MI.
Keyphrases
- mesenchymal stem cells
- umbilical cord
- stem cells
- combination therapy
- bone marrow
- cell therapy
- global health
- drug delivery
- heart failure
- oxidative stress
- randomized controlled trial
- cardiovascular disease
- systematic review
- public health
- ischemia reperfusion injury
- type diabetes
- coronary artery disease
- endothelial cells
- cell death
- endoplasmic reticulum stress
- diabetic retinopathy
- signaling pathway
- atrial fibrillation
- blood brain barrier
- subarachnoid hemorrhage
- vascular endothelial growth factor
- pi k akt